144 related articles for article (PubMed ID: 38277752)
21. Sharing the initial experience of pan-cancer panel analysis in high-risk renal cell carcinoma in the Korean population.
Suh J; Jeong CW; Choi S; Ku JH; Kim HH; Kim K; Kwak C
BMC Urol; 2020 Aug; 20(1):125. PubMed ID: 32811483
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of VEGFR-TKIs plus immune checkpoint inhibitors in metastatic renal cell carcinoma patients with favorable IMDC prognosis.
Ciccarese C; Iacovelli R; Porta C; Procopio G; Bria E; Astore S; Cannella MA; Tortora G
Cancer Treat Rev; 2021 Nov; 100():102295. PubMed ID: 34564043
[TBL] [Abstract][Full Text] [Related]
23. Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in renal cell carcinoma.
Piva F; Giulietti M; Occhipinti G; Santoni M; Massari F; Sotte V; Iacovelli R; Burattini L; Santini D; Montironi R; Cascinu S; Principato G
Oncotarget; 2015 Oct; 6(31):32161-8. PubMed ID: 26452128
[TBL] [Abstract][Full Text] [Related]
24. Frontline immune checkpoint inhibitor-based combination therapy in metastatic renal cell carcinoma patients with poor performance status.
Carril-Ajuria L; Colomba E; Romero-Ferreiro C; Cerbone L; Ratta R; Barthelemy P; Vindry C; Fléchon A; Cherifi F; Boughalem E; Linassier C; Fornarini G; Rebuzzi SE; Gross-Goupil M; Saldana C; Martin-Soberón M; de Velasco G; Manneh R; Pernaut C; Sanchez de Torre A; Flippot R; Escudier B; Albiges L
Eur J Cancer; 2023 Feb; 180():21-29. PubMed ID: 36527973
[TBL] [Abstract][Full Text] [Related]
25. Somatic mutations as preoperative predictors of metastases in patients with localized clear cell renal cell carcinoma - An exploratory analysis.
Mano R; Duzgol C; Ganat M; Goldman DA; Blum KA; Silagy AW; Walasek A; Sanchez A; DiNatale RG; Marcon J; Kashan M; Becerra MF; Benfante NE; Coleman JA; Kattan MW; Russo P; Akin O; Ostrovnaya I; Hakimi AA
Urol Oncol; 2021 Nov; 39(11):791.e17-791.e24. PubMed ID: 34580025
[TBL] [Abstract][Full Text] [Related]
26. Expression of PBRM1 as a prognostic predictor in metastatic renal cell carcinoma patients treated with tyrosine kinase inhibitor.
Cai W; Wang Z; Cai B; Yuan Y; Kong W; Zhang J; Chen Y; Liu Q; Huang Y; Huang J; Xue W
Int J Clin Oncol; 2020 Feb; 25(2):338-346. PubMed ID: 31720994
[TBL] [Abstract][Full Text] [Related]
27. Genomic Profiling and Response to Immune Checkpoint Inhibition plus Tyrosine Kinase Inhibition in FH-Deficient Renal Cell Carcinoma.
Xu Y; Kong W; Cao M; Wang J; Wang Z; Zheng L; Wu X; Cheng R; He W; Yang B; Dong B; Pan J; Chen Y; Huang J; Jiang C; Zhai W; Li F; Chen R; Zhou X; Wu G; Geng X; Chen J; An H; Yuan Y; Xu T; Chen D; Lin D; Xu L; Huang K; Peng L; Yu Y; Tai S; Qi H; Luo K; Kang X; Wang H; Huang Y; Zhang J; Xue W
Eur Urol; 2023 Feb; 83(2):163-172. PubMed ID: 35715365
[TBL] [Abstract][Full Text] [Related]
28. Genomic characterization of clear cell renal cell carcinoma using targeted gene sequencing.
Lin PH; Huang CY; Yu KJ; Kan HC; Liu CY; Chuang CK; Lu YC; Chang YH; Shao IH; Pang ST
Oncol Lett; 2021 Feb; 21(2):169. PubMed ID: 33456545
[TBL] [Abstract][Full Text] [Related]
29. Improvement in survival end points of patients with metastatic renal cell carcinoma through sequential targeted therapy.
Calvo E; Schmidinger M; Heng DY; Grünwald V; Escudier B
Cancer Treat Rev; 2016 Nov; 50():109-117. PubMed ID: 27664394
[TBL] [Abstract][Full Text] [Related]
30. An integrative genomics approach for identifying novel functional consequences of PBRM1 truncated mutations in clear cell renal cell carcinoma (ccRCC).
Wang Y; Guo X; Bray MJ; Ding Z; Zhao Z
BMC Genomics; 2016 Aug; 17 Suppl 7(Suppl 7):515. PubMed ID: 27556922
[TBL] [Abstract][Full Text] [Related]
31. Gene mutation profiling and clinical significances in patients with renal cell carcinoma.
Wang Y; He P; Zhou X; Wang C; Fu J; Zhang D; Liao D; Zhou Z; Wu C; Gong W
Clinics (Sao Paulo); 2023; 78():100259. PubMed ID: 37515929
[TBL] [Abstract][Full Text] [Related]
32. Multiple tumor suppressors regulate a HIF-dependent negative feedback loop via ISGF3 in human clear cell renal cancer.
Liao L; Liu ZZ; Langbein L; Cai W; Cho EA; Na J; Niu X; Jiang W; Zhong Z; Cai WL; Jagannathan G; Dulaimi E; Testa JR; Uzzo RG; Wang Y; Stark GR; Sun J; Peiper S; Xu Y; Yan Q; Yang H
Elife; 2018 Oct; 7():. PubMed ID: 30355451
[TBL] [Abstract][Full Text] [Related]
33. RUNX3 pathway signature predicts clinical benefits of immune checkpoint inhibition plus tyrosine kinase inhibition in advanced renal cell carcinoma.
Wang J; Zhang S; Wang Y; Zhu Y; Xu X; Guo J
BMC Urol; 2024 Jan; 24(1):8. PubMed ID: 38172737
[TBL] [Abstract][Full Text] [Related]
34. Correlating Immune Cell Infiltration Patterns with Recurrent Somatic Mutations in Advanced Clear Cell Renal Cell Carcinoma.
Chakiryan NH; Hajiran A; Kim Y; Aydin AM; Zemp L; Katende E; Nguyen J; Fan W; Cheng CH; Lopez-Blanco N; Chahoud J; Spiess PE; Fournier M; Dhillon J; Wang L; Moran-Segura C; Mulé J; Du D; Yoder SJ; Berglund A; Teer JK; Manley BJ
Eur Urol Focus; 2022 May; 8(3):784-793. PubMed ID: 33994165
[TBL] [Abstract][Full Text] [Related]
35. Identification of genomic drivers for the therapeutic response of Cabozantinib in patients with metastatic renal cell carcinoma.
Borkowetz A; Sommer U; Baretton G; Gruellich C; Bürk BT; Erb HHH; Thomas C;
World J Urol; 2024 Feb; 42(1):94. PubMed ID: 38386122
[TBL] [Abstract][Full Text] [Related]
36. Real-World Outcomes Among US Veterans Health Administration Patients Newly Diagnosed with Metastatic Renal Cell Carcinoma and Treated with First-Line Monotherapy.
Bhanegaonkar A; Pandya S; Zheng Y; Kim R; Krulewicz S; Kasturi V; Phatak H
Adv Ther; 2021 May; 38(5):2644-2661. PubMed ID: 33866526
[TBL] [Abstract][Full Text] [Related]
37. Impact of Clinicopathological Features on Survival in Patients Treated with First-line Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Renal Cell Carcinoma: A Meta-analysis of Randomized Clinical Trials.
Rizzo A; Mollica V; Santoni M; Ricci AD; Rosellini M; Marchetti A; Montironi R; Ardizzoni A; Massari F
Eur Urol Focus; 2022 Mar; 8(2):514-521. PubMed ID: 33714725
[TBL] [Abstract][Full Text] [Related]
38. Outcomes of patients with advanced non-clear cell renal cell carcinoma treated with first-line immune checkpoint inhibitor therapy.
Graham J; Wells JC; Dudani S; Gan CL; Donskov F; Lee JL; Kollmannsberger CK; Meza L; Beuselinck B; Hansen A; North SA; Bjarnason GA; Sayegh N; Kanesvaran R; Wood LA; Hotte SJ; McKay RR; Choueiri TK; Heng DYC
Eur J Cancer; 2022 Aug; 171():124-132. PubMed ID: 35717820
[TBL] [Abstract][Full Text] [Related]
39. Molecular genetics of clear-cell renal cell carcinoma.
Brugarolas J
J Clin Oncol; 2014 Jun; 32(18):1968-76. PubMed ID: 24821879
[TBL] [Abstract][Full Text] [Related]
40. PBRM1, SETD2 and BAP1 - the trinity of 3p in clear cell renal cell carcinoma.
Walton J; Lawson K; Prinos P; Finelli A; Arrowsmith C; Ailles L
Nat Rev Urol; 2023 Feb; 20(2):96-115. PubMed ID: 36253570
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
